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We conducted a prospective multicenter study identifying the role of bortezomib in patients with relapsed or refractory plasma
cell myeloma (PCM) in bone resorption and formation via bone turnover markers. A total of 104 patients received at least 1 cycle
of bortezomib. Most of them had advanced disease (𝑛 = 89). Among them, 75 patients completed 4 cycles of treatment. Most of
the patients (81.7%) were treated in combination with steroid. After the 4th cycle treatment, 47 of 75 patients achieved CR, nCR,
VGPR, and PR (64.4%), while 26 patients achieved less than PR (35.6%). The proportion of patients who achieved ≥ PR increased
as patients received more treatment cycles, reaching 90% after the 8th cycle. DKK-1 levels decreased significantly posttreatment.
Bone formation markers (bALP and OC) and osteoclast regulator such as sRANKL also decreased significantly. These findings
were observed primarily in patients who received steroid and who had a longer disease duration. While sRANKL demonstrated
significant reduction posttreatment, osteoprotegerin (OPG) level did not significantly change posttreatment, resulting in a
decreased sRANKL/OPG ratio (𝑃 = 0.037). In conclusion, our clinical data suggest that treatment with bortezomib and steroid
may rearrange the metabolic balance between osteoblast and osteoclast activities in PCM.
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1. Introduction
Plasma cell myeloma (PCM) is a neoplasm of plasma cells
characterized by the appearance of monoclonal immuno-
globulin, that is, bone pain caused by osteolytic lesions and
pathologic fracture, hypercalcemia, renal insufficiency, and
anemia [1]. Prognosis of PCM is variable, with the survival
ranging from several months to over 10 years.
Myeloma bone disease is the result of increased destruc-
tion of bone that cannot be compensated by new bone
formation, which develops in approximately 80% of the
patients. Myeloma cells activate osteoclasts through various
osteoclast activating substances and suppress the activity of
osteoblasts, causing an imbalance between bone resorption
and formation. This imbalance induces myeloma-related
bone problems, which are themost debilitatingmanifestation
of the disease and have direct relationship with patient’s
quality of life. Therefore, controlling myeloma bone disease
has been regarded to be an important goal of treatment.
Currently, various types of bisphosphonate have been used
for myeloma bone disease [2]. Bisphosphonates inhibit
osteoclastic function which reduces bone resorption and
bone pain, improve patient’s performance, and preserve one’s
quality of life [3–5]. However, bisphosphonates are known to
be associated with renal impairment [2] and an increase in
the risk of osteonecrosis of the jaw [6]. Furthermore, these
agents have been shown to have little impact on osteoblasts.
Bortezomib (Velcade) has been approved to treat PCM
as it activates osteoblasts [7–13] and suppresses osteoclasts
[7, 10, 11, 13–15], in addition to an antimyeloma effect,
ultimately leading to bone formation [16–18]. Preclinical
studies indicate that bortezomib induces mesenchyme stem
cells to preferentially undergo osteoblastic differentiation,
resulting in increased bone formation and rescue from bone
loss [19]. Clinically, bortezomib containing treatment for
relapsed or refractory PCM demonstrated an improvement
in bone lesions on radiologic examination [20] with an
association of direct bone anabolism. These studies indicate
that bortezomib provides a differential advantage from other
agents used for treatment of PCM. It should be preferentially
considered as a treatment method as bone disease has signifi-
cant impact on mortality and morbidity of the patients. Until
now, there have been no other antimyeloma agents to have
anabolic effect on bone. In clinical practice, however, most of
treatment regimens contain steroid, which exerts differential
effects on bonemetabolism. As far as we know, there have not
beenmuch data exploring the role of bortezomib in combina-
tion with or without steroid specifically in bone metabolism.
Therefore, we conducted a prospective multicenter study to
identify the role of bortezomib along with steroid among
patients with relapsed or refractory PCM in bone resorption
and formation using bone turnovermarkers prior to and after
treatment.
2. Patients and Methods
2.1. Patients. Eligible patients were at least 18 years old
and treated with bortezomib as a second line treatment for
relapsed or refractory PCM. All patients provided a written
informed consent to blood sampling to measure serum bone
markers before and after therapy. Exclusion criteria included
hypersensitivity to bortezomib, inadequate organ function,
and pregnancy. The study was approved by each institutional
review board of the participation centers in accordance with
the Declaration of Helsinki.
2.2. Study Design and Treatment. Between March 2008 and
June 2009, this multicenter prospective study was conducted
at 20 centers in the Republic of Korea to investigate the role of
bortezomib in bone resorption and formation.The details on
treatment schedule were given elsewhere [9]. Briefly, borte-
zomib was administered as intravenous bolus (1.3mg/m2
twice weekly in a 21-day cycle) in various combinations with
other chemotherapeutic agents including steroid, thalido-
mide, or alkylating agents. If patients experienced grade 4
hematologic toxicities or nonhematologic toxicities ≥grade
3 other than peripheral neuropathy related to bortezomib,
bortezomib was withheld until toxicity recovered to grade
≤1. Once the toxicity resolved, bortezomib was readminis-
tered with a reduced dose of 25% (1.3mg/m2 to 1.0mg/m2;
1.0mg/m2 to 0.7mg/m2).
The primary end point was changes in the levels of bone
markers before and after 4 cycles of bortezomib infusion.
Secondary end points included complete response (CR) rate,
overall response rate, correlation between changes in bone
markers and response rate, numeric rating scale (NRS) pain
score, and safety profiles.
2.3. Assessment. Blood samples were obtained before and
after bortezomib infusion at baseline, after 4 cycles, and after
5–8 cycles of treatment, respectively. Patients who received
at least 4 cycles of bortezomib with blood samples from
each bortezomib infusion were included for the evalua-
tion. As an osteoclast regulator, soluble receptor activator
of nuclear factor-𝜅B ligand (sRANKL) and osteoprotegerin
(OPG) were measured. Dickkopf-1 (DKK-1) was measured
as an osteoblast inhibitor. Bone-specific alkaline phosphatase
(bALP) and osteocalcin (OC) were measured as bone forma-
tion indices.
Assessment of response, relapse, and progression was
based on serum and/or urine M-protein quantification, bone
marrow evaluation, and skeletal survey using European Bone
and Marrow Transplantation (EBMT) criteria [21] and Inter-
national Myeloma Working Group (IMWG) criteria [22].
Pain was graded using NRS (numeric rating scale), and pain
scale was measured before day 1 of each bortezomib cycle.
The pain was regarded as mild, moderate, and severe if the
visual analogue scale (VAS) was 0 to 3, 4 to 6, and 7 to 10,
respectively.
2.4. Statistical Analysis. Differences between pre- and post-
bortezomib values of the studied parameters were evaluated
using the Wilcoxon rank sum test. Differences between pre-
treatment and posttreatment values within each group were
analyzed. Results were considered statistically significant
when 𝑃 < 0.05.
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3. Results
A total of 104 patients received cycle 1 bortezomib treatment
(Table 1). Among them, 75 patients (72.1%) completed the
4th treatment cycle and 23 patients (22.1%) finished 8 cycles
of treatment. The reasons for not completing the whole
treatment cycle were the termination of the clinical study as
decided by the investigators (𝑛 = 18), adverse drug reactions
or death of any cause (𝑛 = 16), obtaining CR before the 8th
treatment cycle (𝑛 = 7), withdrawal by patients (𝑛 = 5), loss
of followup (𝑛 = 3), and other reasons (𝑛 = 32). The median
of treatment cycles for all patients was 4.6 ± 2.2. The majority
of the patients were stages II and III (𝑛 = 89, 85.6%) via
the international staging system. The first line of treatment
included vincristine + adriamycin + dexamethasone (VAD),
melphalan + prednisolone (MP), and autologous stem
cell transplantation (ASCT). Most of the patients received
bortezomib in combination with other agents, with the most
common one being steroid (81.7%).
3.1. Response to Bortezomib Treatment. Of 75 patients who
finished the 4th cycle treatment, 64% of patients who finished
the 4th cycle treatment achieved ≥PR, while the remaining
36% did not reach PR (Figure 1). Meanwhile, the proportion
of patients who achieved ≥PR increased as patients received
more treatment cycles, reaching 90% after the 8th cycle.
The median VAS for pain at baseline and after the 4th
cycle was 3.1 ± 2.3 and 3.1 ± 2.2, respectively. Although there
was no significant reduction in bone pain in terms of total
VAS after cycle 4, the proportion of patients who reported
severe bone pain (VAS ≥ 7) decreased from 11.5% to 6.7%
after cycle 4. The number of skeletal lesions did not show
significant changes (2.5±1.9 at baseline, 2.5±1.9 after cycle 4,
and 3.3 ± 2.9 after cycle 8, resp.) after bortezomib treatment.
Most of the patients experienced peripheral neuropathy with
the progress of treatment, but the severity of peripheral
neuropathy was grade I/II in most cases (58.7% after cycle
4 and 73.9% after cycle 8, resp.; Figure 2). The proportion
of grade II neuropathy decreased while that of grade I
neuropathy increased as treatment progressed.
3.2. Changes in Bone Markers. There were no significant
differences in bone turnover markers (OC, bALP, DKK-
1, sRANKL, OPG, and sRANKL/OPG ratio) at baseline
according to gender and age except for OPG.OPG levels were
significantly higher in patients aged ≥65 years (𝑃 = 0.002).
Changes in the level of bone markers before treatment and
posttreatment are shown in Table 2. sRANKL demonstrated
a significant reduction posttreatment (𝑃 = 0.011), and OPG
levels did not change significantly, resulting in a decreased
sRANKL/OPG ratio (𝑃 = 0.037). Despite a significant
decrease in levels of DKK-1 (𝑃 = 0.035), an osteoblastic
inhibitor, after bortezomib treatment, the levels of OC and
bALPwere also significantly lower posttreatment (𝑃 < 0.0001
and 0.004, resp.). The inconsistency in changes of DKK-1
and OC/bALP may result from the long disease duration
(relapsed and/or refractory status) and advanced disease
status (stages III and IV, 85.6%). The type of agents used in
Table 1: Patient characteristics.
Total enrolled patients, 𝑛 (%) 104
Cycle 1 104 (100.0)
Cycle 4 75 (72.1)
Cycles of bortezomib treatment, mean ± SD 4.6 ± 2.2
Sex, 𝑛, M/F (%) 56/48 (53.9/46.1)
Age at treatment, 𝑛, <65/≥65 (%) 67/37 (64.4/35.6)
ECOG performance status, 𝑛 (%)
0 23 (22.1)
1 56 (53.9)
2 23 (22.1)
3 2 (1.9)
4 0
Quantity of M-protein (g/L) in SPEP, median
(range) 1.3 (0.0–6.7)
Hb ≤ 10.0 g/dL, 𝑛/median (%/range) 41/10.7(39.4/6.9–15.3)
Platelet, median, 𝑛 (range) 203.0 (30.0–760.0)
Creatinine, median (range) 0.98 (0.5–5.6)
Calcium (g/dL), median (range) 8.7 (6.5–11.1)
LDH > 472 IU/L, 𝑛/median (%/range) 20/350.0(19.2/15.0–1452.0)
Albumin (g/L), median (range) 3.7 (2.4–6.4)
Stage, 𝑛 (%)
Durie-Salmon Staging System
I 13 (12.5)
II 21 (20.2)
III 70 (67.3)
Stage, 𝑛 (%)
International Staging System
I 15 (14.4)
II 44 (42.3)
III 45 (43.3)
Previous treatment, 𝑛 (%)
VAD 37 (35.6)
MP 30 (28.9)
Dexamethasone 29 (27.9)
ASCT 21 (20.2)
Thalidomide 19 (18.3)
Others 21 (20.2)
VAD: vincristine + Adriamycin + dexamethasone; MP: melphalan + pred-
nisolone; ASCT: autologous stem cell transplantation.
combination with bortezomib also could be associated with
the discordance. Therefore, we analyzed the changes in OC
and bALP before and after bortezomib treatment according
to disease duration and combination with corticosteroid.
The levels of OC and bALP decreased more significantly
in longer diagnosis-treatment period group (≥6 months,
longer prevalence period group) than those in the shorter
group (Table 3). Influences of steroid in combination with
bortezomib on bone markers are also shown in Table 3.
Serum OC and bALP levels decreased significantly in the
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Figure 1: Response to bortezomib treatment.
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Figure 2: Peripheral neuropathy according to bortezomib treatment
cycles.
steroid combination group (𝑃 = 0.0002 and 0.001, resp.),
while the same bone marker changes were not significant in
the bortezomib single-treatment group.
4. Discussion
There have been multiple studies of bortezomib, alone
and in combination, in both previously untreated and
relapsed/refractory PCM patients and its effect on bone
remodeling markers [8, 10, 12, 13, 18, 23–26]. Most studies
revealed that biomarkers of osteoblastic activity increased
and the levels of osteoblast inhibitors decreased, while the
levels of markers of osteoclastic activity have also been
shown to decrease. Bortezomib treatment is associated with
increased ALP and OC, while depressing sRANKL and OPG.
Additionally, bortezomib was associated with a decrease in
DKK-1 levels.
In our study, despite bortezomib treatment, the levels
of biomarkers related to bone formation (bALP and OC)
substantially decreased, especially in the patients with longer
prevalence period and steroid combination. Most of the
patients (81.7%) in our study were treated in combination
with corticosteroid. Overall patterns in changes of bone
markers (decreased levels in OC and bALP) were similar to
those in steroid combination group, but these patterns were
not observed in bortezomib single-treatment group and the
shorter prevalence group. In general, the effects of steroid are
represented by a reduction in bone formation markers and a
trend towards an increase or no change in bone resorption
markers, which implies that steroids have a dominant effect
on bone formation rather than bone resorption [27]. As
a result, corticosteroid has been known to depress serum
OC level, mainly due to the reduction in the rate of bone
formation [28]. bALP, an enzyme released from osteoblasts,
decreased in patients receiving steroid due to the reduction
in the number of osteoblasts. Therefore, the reduction seen
in the level of bone formation-related markers, bALP and
OC in our study, is thought to result from the dominant
effect of corticosteroid over bortezomib on bone formation.
In a similar context, patients with longer prevalence duration
also have a probability of longer exposure to steroid at a
higher dose, which could explain the similar pattern in
biomarkers in that group. The fact that significantly low
levels of OC and bALP were found in the longer prevalence
group before bortezomib therapy could also explain the
decreased level posttreatment in the group. Terpos et al. also
showed that the combination of bortezomib with melpha-
lan, dexamethasone, and intermittent thalidomide (VMDT)
did not increase the bone formation markers (bALP and
OC) although a reduction in DKK-1 levels was observed
[12]. On the other hand, bortezomib was associated with a
decrease in DKK-1 levels. Consistent with these results, our
study showed decreased serum DKK-1 level posttreatment.
However, patients in steroid combination group did not
show statistical significance in DKK-1 level (data not shown).
Decreased production of DKK-1 by bortezomib might be
offset by increased production of DKK-1 by steroid. Gener-
ally, concentrations of osteoclast regulators such as sRANKL
and OPG were shown to be reduced following treatment
with bortezomib in previous reports [12]. In our study,
sRANKL level diminished significantly, whereas there were
no significant changes in OPG levels posttreatment, resulting
in marked reduction in sRANKL/OPG ratio. The reasons for
the inconsistency of results in our study remain unclear but
may be explained by the predominant effect of steroid on
bone formation rather than increased bone resorption. As
for bone formation markers, such as OC and bALP, they
appear to decrease significantly due to the predominant effect
of steroid on bone formation, while the effect of bortezomib
predominates for osteoclast regulators such as sRANKL.
As the treatment in our study also included combina-
tion with dexamethasone in most cases and some patients
received thalidomide, it is difficult to interpret exactly the
role of bortezomib in the bone markers. The effect of cor-
ticosteroid on biochemical markers of skeletal turnover can
be varied according to a number of biases. These include the
different effects on differentmarkers; different steroids, expo-
sure time, and amount of administered steroids; different
routes of administration, evaluation of the effect on normal
subjects (men versus women, fertile versus postmenopausal
BioMed Research International 5
Table 2: Changes in bone markers.
Variables Pretreatment Posttreatment Difference† 𝑃
𝑛 (%) 75 (100.0) 73 (97.3) 73 (97.3)
Osteocalcin ECLIA (ng/mL) 17.7 ± 18.6 13.7 ± 16.0 4.0 ± 15.9 <0.0001
Bone ALP (U/L) 25.9 ± 16.2 21.8 ± 11.2 4.2 ± 14.3 0.004
DKK-1 (pmol/L) 136.4 ± 86.3 116.3 ± 58.8 20.2 ± 78.6 0.035
sRANKL (total, pmol/L) 75.1 ± 86.8 48.4 ± 47.2 28.1 ± 101.6 0.011
OPG (pmol/L) 3.9 ± 1.8 4.0 ± 1.9 −0.1 ± 1.1 0.464
sRANKL/OPG ratio 22.2 ± 34.4 13.5 ± 16.1 9.4 ± 36.6 0.037
ECLIA: electrochemiluminescence immunoassay.
†Pretreatment value − posttreatment value.
Table 3: Changes in bone markers according to the duration of the disease and steroid combination.
Osteocalcin 𝑃∗ Bone ALP 𝑃∗∗
Disease duration
0.009 0.050
<6 months
Pretreatment 18.6 ± 13.9 29.3 ± 18.8
Posttreatment 19.6 ± 24.3 25.7 ± 13.0
Difference 1.2 ± 24.1 4.2 ± 17.0
𝑃
∗ 0.058 0.088
≥6 months
Pretreatment 13.9 ± 19.6 23.4 ± 14.0
Posttreatment 10.1 ± 9.7 18.0 ± 6.4
Difference† 4.9 ± 13.3 5.5 ± 12.4
𝑃
∗
<0.0001 0.002
Steroid
Combination
Pretreatment 16.5 ± 18.0 27.3 ± 18.0
Posttreatment 13.6 ± 15.6 22.0 ± 10.5
Difference 4.2 ± 18.7 5.4 ± 15.7
𝑃
∗ 0.0002 0.001
Without combination
Pretreatment 15.5 ± 12.1 22.7 ± 9.3
Posttreatment 20.5 ± 30.9 20.9 ± 13.2
Difference −2.8 ± 22.3 2.1 ± 9.0
𝑃
∗ 0.153 0.275
∗
𝑃 value represents difference from pretreatment value to posttreatment value within each group.
∗∗
𝑃 value represents difference of treatment outcome by prevalence duration.
†Posttreatment value − pretreatment value.
subjects, or young versus adults) or on patients with disease;
or the inability to control parameters (gonadal function,
parathyroid function, vitamin D status, etc.) that per se
influence turnover [27].
Overall, these clinical data suggest that the combination
treatment with bortezomib and steroid could rearrange the
metabolic balance between osteoblast and osteoclast activi-
ties in PCM and the effects of corticosteroid predominate in
inhibiting bone formation. Bortezomib appears to dominate
in inhibiting bone resorption, while the effect of steroid is
minimal in the inhibition of bone resorption.
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